Horizon jumps after teprotumumab data tee up BLA

Horizon Pharma plc (NASDAQ:HZNP) added $7.16 (33%) $29.01 on Thursday after reporting that teprotumumab (HZN-001) met the primary and all secondary endpoints in the Phase III OPTIC trial to treat Graves orbitopathy, also known as thyroid eye disease. The company plans to submit a BLA to FDA mid-year for the human mAb targeting insulin-like growth factor-1 receptor (IGF1R; CD221).

The stock move added more than $1.2 billion to Horizon's market cap...